BDBM658043 1-(4-fluoro-2-meth- ylphenyl)-3-(2- methyl-6-oxo-1,6- dihydropyridin-3- yl)-4-oxo-1,2,3,4- tetrahydropyrido- [4,3-d]pyrimidine- 7-carbonitrile::US20240083896, Example 19

SMILES Cc1cc(F)ccc1N1CN(C(=O)c2cnc(cc12)C#N)c1ccc(=O)[nH]c1C

InChI Key InChIKey=NVPDFQSUVSJHSM-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 658043   

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658043(US20240083896, Example 19 | 1-(4-fluoro-2-meth- yl...)
Affinity DataIC50: 3.98E+3nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent